12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Incivek regulatory update

Johnson & Johnson reached an agreement on the price for HCV drug Incivo telaprevir with Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband). The company declined to disclose the price, but did characterize the result...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >